Overview
Home » News » Drugs in the Pipeline Publish Date November 7, 202 Empagliflozin Cuts Risk of Kidney Disease Progresion, CV Death in CKD Patients Brian Park, PharmD Share on Facebok Share on Twiter Share on LinkedIn Share on Redit Print Share by Email Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Credit: Gety Images Positive results were anounced from a phase 3 trial evaluating the efect of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, on kidney disease progresion or cardiovascular (CV) death in patients with pre-existing chronic kidney disease (CKD).
Key Information
The multicenter, randomized, paralel-group, double-blind, placebo-controled EMPA-KIDNEY trial (ClinicalTrials.gov Identifier: NCT0359410) enroled more than 60 patients 18 years of age and older with CKD at risk of kidney disease progresion. The study population included patients with or without diabetes, with mildly to severely reduced eGFR, and with normal and increased levels of albumin. Patients were randomly asigned to receive empagliflozin 10mg or placebo once daily.
The primary composite endpoint was the time to first ocurence of kidney disease progresion (defined as end stage kidney disease with a sustained decline in eGFR <10mL/min/1.73m2, renal death, or a sustained decline of ≥40% in eGFR) or CV death. Results showed that treatment with empagliflozin reduced the risk of kidney disease progresion or CV death by 28% compared with placebo (hazard ratio [HR], 0.72; 95% CI, 0.64-0.82; P <.01).
Summary
Aditionaly, a 14% reduction in al-cause hospitalization (secondary endpoint) was observed with empagliflozin when compared with placebo (HR, 0.86; 95% CI, 0.78-0.95; P =.025). Diferences in other key secondary endpoints including hospitalization for heart failure or CV death or al-cause death were found not to be statisticaly significant. The overal safety profile of empagliflozin was generaly consistent with its established profile.